Concentration-dependent effects of tiludronate on equine articular cartilage explants incubated with and without interleukin-1β.

This study investigates the effects of various concentrations of a drug called tiludronate on horse cartilage explants with or without a specific equine interleukin. The drug exhibited a range of effects, with low doses showing some protective effects on the cartilage, and high doses proving detrimental. More research is needed before its application can be recommended.

Study Overview and Methodology

• The study aims to determine the collective effects of different concentrations of a drug known as tiludronate on equine (horse) cartilage explants (tissues grown in an artificial environment). The explants are also treated either with or without an equine interleukin (a type of protein that plays a key role in cell signaling).
• The test subjects were cartilage explants from the femorotibial joints of three young adult horses.
• The explants were exposed to one of six concentrations of tiludronate and with or without the addition of equine interleukin for 96 hours.
• Prostaglandin E(2) (PGE(2)) concentrations, sulfated glycosaminoglycan (sGAG) concentrations, chondrocyte apoptosis, and gene expression of various substances were evaluated to assess the effects of the different treatments.

Results

• The equine interleukin led to an increase in PGE(2) concentration, sGAG release from explants, increased chondrocyte apoptosis (cell death), and increased expression of matrix metalloproteinases (MMPs) genes.
• Lower concentrations of tiludronate reduced the interleukin-induced sGAG release and chondrocyte apoptosis, while the higher concentrations of tiludronate increased these factors. Furthermore, the highest tiludronate concentration observed increased interleukin-8 gene expression, regardless of whether equine interleukin was present.
• The research revealed that tiludronate has biphasic concentration-dependent effects on cartilage explants, independent of PGE(2) secretion or MMP gene expression.

Conclusions

• Low tiludronate concentrations had some chondroprotective effects, but high tiludronate concentrations were harmful to equine articular cartilage.
• Intra-articular administration of tiludronate to horses may have detrimental effects, based on the dosage used.
• Though this experiment provides essential data, further in vivo studies are needed to confirm these results before tiludronate can be administered to horses for therapeutic purposes.